

1 TITLE PAGE

2

# 3 Five-Year Survival Outcomes for Breast Cancer 4 Patients Across Continental Africa: A Contemporary 5 Review of Literature with Meta Analysis

6  
7 **Augustina Badu-Peprah**<sup>1,2,†</sup>, **Ernest Kissi Kontor**<sup>3,†,\*</sup>, **Adu-Gyamfi Benjamin**<sup>2</sup>, **Jessica Kumah**<sup>4</sup>,  
8 **Akosua Aya Essuman**<sup>5</sup>, **Bossoh Selorm**<sup>3</sup>, **Issahak Nurudeen**<sup>3</sup>, **Bismark Osei Owusu**<sup>6</sup>, and  
9 **Nityanand Jain**<sup>7,\*</sup>

10 <sup>1</sup> Department of Radiology, Kwame Nkrumah University of Science and Technology, Kumasi, AOK385 Ghana

11 <sup>2</sup> Department of Radiology, Komfo Anokye Teaching Hospital, Kumasi, AOK385 Ghana

12 <sup>3</sup> Department of Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, Kumasi,  
13 AOK385 Ghana

14 <sup>4</sup> Department of Environmental Health Sciences, University of Massachusetts Amherst, MA 01003 United States

15 <sup>5</sup> Department of Biology, Georgia State University, Atlanta, GA 30302 United States

16 <sup>6</sup> Internal Medicine Directorates, Komfo Anokye Teaching Hospital, Okomfo Anokye Road, Kumasi AK034, Ghana

17 <sup>7</sup> Independent Statistical Consultant, Chandigarh, Chandigarh Capital Region, 160036 India

18

19 **\*Corresponding Authors**

20 **† Co-first authors (contributed equally)**

21

## 22 Additional Author Information

23

24 **Augustina Badu-Peprah**, Email: [augustinabadupeprah@gmail.com](mailto:augustinabadupeprah@gmail.com); ORCID: 0000-0003-0979-4006

25

26 **Ernest Kissi Kontor**, Email: [ernestkissikontor@gmail.com](mailto:ernestkissikontor@gmail.com); ORCID: 0000-0001-7349-8012

27

28 **Adu-Gyamfi Benjamin**, Email: [adugyamfibenjamin210@gmail.com](mailto:adugyamfibenjamin210@gmail.com); ORCID: 0009-0000-0417-8074

29

30 **Jessica Kumah**, Email: [jkumah@umass.edu](mailto:jkumah@umass.edu); ORCID: 0009-0003-7346-3188

31

32 **Akosua Aya Essuman**, Email: [akosuaaya29@gmail.com](mailto:akosuaaya29@gmail.com); ORCID: 0009-0008-9709-6905

33

34 **Bossoh Selorm**, Email: [selormbossoh@gmail.com](mailto:selormbossoh@gmail.com); ORCID: 0009-0003-6872-6051

35

36 **Issahak Nurudeen**, Email: [nurudeenissahak09@gmail.com](mailto:nurudeenissahak09@gmail.com); ORCID: 0009-0008-1280-2031

37

38 **Bismark Osei Owusu**, Email: [bhismarkoseiowusu@gmail.com](mailto:bhismarkoseiowusu@gmail.com); ORCID: 0009-0008-2589-799X

39

40 **Nityanand Jain**, Email: [nityapkl@gmail.com](mailto:nityapkl@gmail.com); ORCID: 0000-0002-7918-7909

41

42

43

44

45 **Abstract**

46 **Background**

47 Breast cancer associated mortality in Africa remains high due to poor survival rates, varying  
48 widely across countries. Despite medical advancements, barriers like limited access to early  
49 detection and treatment persist. This meta-analysis offers a crucial update on 5-year survival  
50 trends and influencing factors across continental Africa.

51

52 **Methods**

53 A systematic search of four biomedical databases and citation searching identified 79 articles  
54 from 22 African countries, analyzing 27,559 patients (97% female). A random-effects model was  
55 used to estimate the 5-year survival rate with subgroup analyses. Publication bias was assessed  
56 using Egger's test and funnel plots.

57

58 **Results**

59 Pooled overall 5-year breast cancer survival in Africa averaged 48% (95% CI: 43-53%) with  
60 high statistical heterogeneity ( $I^2 = 98\%$ ). Survival was highest in Northern Africa (64%; 95% CI:  
61 59-69%) and lowest in Western Africa (32%; 95% CI: 23-42%). Males (51%; 95% CI: 36-65%)  
62 had marginally higher survival than females (48%; 95% CI: 42-54%). Socioeconomic indices  
63 were positively associated with better outcomes. Publication bias, adjusted by the trim-and-fill  
64 method, raised survival to 62% (95% CI: 55-67%). A country-wise comparison with 2018  
65 estimates suggests a declining survival tendency, with WHO AFRO countries reporting the  
66 poorest estimates among other WHO regions. Despite regional differences, survival trends seem  
67 to have plateaued near 48-49% level continent-wide since the early 2010s.

68

69 **Conclusions**

70 Our findings reveal marked regional disparities in survival rates across Africa, underscoring the  
71 urgent need for targeted healthcare interventions. Strengthening healthcare systems, ensuring  
72 universal access, and driving socioeconomic progress are vital to improving survival outcomes.

73

74 **Keywords:** breast cancer; Africa; survival; surveillance; cumulative meta-analysis.

75

76 **1. Introduction**

77 Breast cancer remains a significant global health concern that affects both women and  
78 men, despite the considerable progress made in early diagnostics and treatment modalities [1]. It  
79 is the most prevalent malignant disease among women worldwide and is the second leading  
80 cause of cancer-related mortality [2,3]. The heterogeneity and complexity in managing breast  
81 cancer is underscored by its multiple subtypes, which exhibit varying biological behaviors and  
82 clinical responses to treatment [4,5]. Notwithstanding substantial advancements in early  
83 detection and therapeutic strategies, significant survival disparities persist between high-income  
84 and low- to middle-income countries [6,7].

85 In Africa, the burden of breast cancer is particularly pronounced, with incidence and  
86 mortality rates continuing to rise. The latest estimates indicate that breast cancer leads to an  
87 estimated 186,598 new cases and 85,787 deaths annually among Africans [8]. Notably, regional  
88 variations in disease burden have been observed within the continent, with the highest incidence  
89 of new cases occurring in Northern and Western Africa [9]. Contributing factors include delayed

90 diagnosis, inadequate healthcare infrastructure and funding, insufficient public health education  
91 initiatives, mistrust in western medicine, and significant socioeconomic barriers.

92 The most recent 5-year survival estimates for African countries were reported by a meta-  
93 analysis conducted by Ssentongo et al. [10]. Their study, which was limited to a search strategy  
94 till October 2018, determined that the overall 5-year survival rate in Africa was 52.9%.  
95 Subsequently, no further estimates have been collated, potentially resulting in a discrepancy  
96 between the literature and the situation on the ground. Cochrane suggests that updates should  
97 occur biennially, while Campbell reviews recommend that updates occur within a five-year cycle  
98 to facilitate the accumulation of knowledge [11].

99 These updates are driven by the rapid evolution of medical research and treatment  
100 methodologies, which may not align with current practices, advancements, or emerging trends  
101 observed six years ago. Additionally, the socioeconomic and healthcare landscapes in Africa are  
102 subject to continual change influenced by several factors, including policies, investments, and  
103 regional partnerships. These dynamics can significantly impact breast cancer diagnosis,  
104 treatment, and survival outcomes, highlighting the necessity for an updated analysis.

105 Hence, we believe that the integration of more recent data allows for a detailed and  
106 updated analysis of survival outcomes in Africa. The findings from our study will provide  
107 insights that can be acted upon, offering a detailed understanding of the factors influencing breast  
108 cancer survival across diverse African contexts. Such information is crucial for the development  
109 of targeted interventions, the shaping of policy decisions, and ultimately the improvement of  
110 patient outcomes across the region.

## 111 2. Methods

112 The protocol for the present systematic review and meta-analysis was registered  
113 prospectively on PROSPERO (registration number – CRD42024595654). The Preferred  
114 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were  
115 followed throughout the search and study selection process to ensure transparency and  
116 completeness. Discrepancies between the registered protocol and research methodology are  
117 reported in **Appendix 1**.

118

### 119 2.1. Data Sources and Search Strategy

120 A literature search was undertaken across multiple biomedical databases, including  
121 PubMed, Medline, Web of Science, and Scopus, to identify studies reporting 5-year survival  
122 estimates for breast cancer across African countries. The search was restricted to articles  
123 published from database inception to October 2024 to ensure the inclusion of the most recent  
124 data. We used the SPIDER framework (Sample, Phenomenon of Interest, Design, Evaluation,  
125 Research Type) to structure our search strategy as follows:

126

127 **Sample (S):** Patients diagnosed with breast cancer in Africa.

128 **Phenomenon of Interest (PI):** 5-year survival estimates.

129 **Design (D):** Observational studies, retrospective and prospective.

130 **Evaluation (E):** 5-year survival rates and socio-demographic factors influencing survival.

131 **Research Type (R):** Quantitative studies that report survival rates.

132

133 We used a combination of author keywords and Medical Subject Headings (MeSH) terms  
134 such as “breast cancer,” “five-year survival,” “Africa,” “Kaplan Meier,” and “survival.” To  
135 enhance the comprehensiveness of our search, we performed a citation search by examining the

136 reference lists of all relevant studies and published systematic reviews and meta-analyses  
137 (**Appendix 2**). Given that literature from low-resource settings tends to be reported in non-  
138 indexed gray literature, we non-comprehensively and manually searched Google Scholar. The  
139 search comprised of the string – (“*survival*”) AND (“*breast cancer*”) AND (“*name of country*”)  
140 and restricted to availability of these terms in the title of the paper. This was done for all 54  
141 countries in Africa to ensure that no data is missed from countries that were not included in  
142 previous meta-analyses. No language restrictions were applied, but studies had to include an  
143 English abstract.

144

## 145 **2.2. Study Selection**

146 Studies were imported into the Covidence software and duplicates were automatically  
147 removed (except Google Scholar searches). EKK, AAE, JK, and SB independently screened the  
148 titles and abstracts of all identified articles. Full-text articles were then retrieved for studies that  
149 appeared to meet the inclusion criteria based on their abstracts. Studies were included if they  
150 reported 5-year survival rates for breast cancer patients, were conducted within African  
151 countries, provided sufficient data to calculate proportions, and were published in any language.  
152 Studies that did not provide separate survival rates for breast cancer, or were editorials,  
153 commentaries, randomized control trials or reviews without original data, were excluded.  
154 Conference abstracts were included if no corresponding full-text paper was found. For full-text  
155 screening, PDFs of the non-English articles were uploaded and translated using PDFSimpli  
156 (<https://pdfsimpli.com/pdf-editor/translate-pdf/>; accessed 09th November 2024).

157 Each study was carefully evaluated against the inclusion and exclusion criteria. Any  
158 discrepancies between reviewers during the study selection process were resolved through  
159 discussion with ABP and BAG. If consensus could not be reached, a third reviewer, NJ was  
160 consulted to make the final decision. The study selection process was meticulously documented  
161 using a PRISMA flow diagram to illustrate the number of records identified, screened, and  
162 assessed for eligibility and inclusion. For Google Scholar searches, results were not considered  
163 for inclusion in PRISMA flow diagram, primarily due to the non-comprehensive nature of our  
164 search and unavailability of results for majority of countries. For countries with results, the full  
165 texts were directly screened by NJ and EKK against the inclusion criteria and the final list of  
166 included studies from other databases. No new studies were identified from Google Scholar.

167

## 168 **2.3. Data Extraction**

169 Data from eligible studies were independently extracted by two reviewers using a  
170 standardized data extraction Excel form. Extraction was done in pairs by EKK and SB, ABP and  
171 BAG, and AAE and JK. Extracted data included study characteristics such as authors, year of  
172 publication, country, gender, region, race, median age, sample size, overall survival (OS), and  
173 number of participants alive at the end of 5-year follow-up period (n). The country’s Human  
174 Development Index (HDI) values was classified according to its HDI ranking in 2022 [12].  
175 Socio-demographic Index (SDI), a measure from the Global Burden of Disease collaboration,  
176 was categorized into quantiles to provide a comprehensive understanding of the demographic  
177 context [13]. We also extracted the survival rates using Webplotdigitizer v.4.5., following the  
178 method described by Tierney et al. [14].

179 To account for sex differences in our analysis, we categorized studies with mixed male  
180 and female participants based on a threshold criterion. Specifically, studies were classified under  
181 a specific sex group if one sex constituted at least 80% of the sample population. This cutoff was

182 selected to ensure that the overall survival outcomes would be predominantly driven by the  
183 characteristics of the majority sex group, thereby reducing potential confounding effects from  
184 mixed-sex samples. This method, though implicitly employed by other studies [10,15], validates  
185 its use in our work. Furthermore, we believe that such a methodological approach allows for a  
186 more accurate representation of the primary variable of interest in the sex-specific survival  
187 analysis. When necessary, corresponding authors were contacted to obtain additional information  
188 or clarifications. Any discrepancies in data extraction were resolved through consultation with a  
189 third reviewer, NJ. The extracted data were then reviewed and validated by the research team to  
190 ensure accuracy and consistency.

191

## 192 **2.4. Quality Assessment**

193 The quality assessment of the included studies was adapted from the methodology  
194 outlined by Ssentongo et al. (**Appendix 3**) [10]. This method was selected for its specificity to  
195 breast cancer meta-analysis and its ability to provide numerical outcomes that can be used to  
196 assess study-level covariates. The approach evaluates studies based on three primary criteria –  
197 detailed demographic information, stratified reporting of survival, and sample size. Each  
198 criterion has a maximum score, with demographic information scoring up to 11 points, stratified  
199 reporting of survival up to 7 points, and sample size up to 6 points. The higher the number of  
200 points, the better the quality of the assessed study.

201

## 202 **2.5. Data Analysis**

203 The survival rates were pooled using the random effects inverse variance method,  
204 employing the “*metaprop*” function in the *<meta>* package of R v.4.4.0. Proportions were  
205 transformed using the logit transformation, and the 95% confidence interval (CI) was based on  
206 the Clopper-Pearson interval (exact binomial interval). To estimate heterogeneity variance, we  
207 used the Restricted Maximum Likelihood (REML) method, which is more suitable for sub-  
208 groups involving a small number of studies, as the DerSimonian method can be misleading  
209 [16,17]. Subgroup analyses were conducted based on geographic region (Northern, Eastern,  
210 Central, Western, Southern Africa), patient sex and ethnicity, Human Development Index (HDI),  
211 Social Development Index (SDI), individual countries, and year of publication.


212 Statistical heterogeneity was assessed using the  $I^2$  statistic and Cochran's Q test.  
213 Publication bias was evaluated with funnel plots and Egger's test, with adjustments made using  
214 the fill and trim method. Additionally, a limit meta-analysis was conducted. Meta-regression  
215 analyses examined the influence of study-level covariates on survival outcomes. The *<metafor>*  
216 and *<orchard>* packages were used for the meta-regression. A cumulative meta-analysis was  
217 conducted to assess changes in survival rates in Africa over time. We compared our results to  
218 previously reported estimates for Africa and other World Health Organization (WHO) regions  
219 using one-sample Z test.

220

## 221 **3. Results**

222 A total of 3884 records were identified through a comprehensive search of four  
223 biomedical databases and citation searching. After a thorough screening of abstracts, titles, and  
224 full texts, 79 records were deemed eligible for inclusion (**Figure 1**) [18-96]. As some records  
225 presented data for multiple countries or demographics within a single record, we designated a  
226 reference as a "record", while each corresponding data was termed as a "study". Accordingly, we  
227 included 88 studies in the pooled meta-analysis. Similarly, 91 studies were analyzed for sex-

228 specific survival outcomes. Data from 27,559 individuals was pooled in our study, with a female-  
 229 to-male ratio of 26,709 to 850 (97% to 3%), respectively. The articles were sourced from 22 of  
 230 the 54 countries in Africa. Study and sampling characteristics are summarized in **Appendix 4**.




231  
 232 **Figure 1. PRISMA flowchart.** Flowchart showing the number of records identified, screened, and  
 233 deemed eligible for pooled meta-analysis.

234  
 235 **3.1. Meta-analysis**

236 The overall pooled survival rate was 48% (95% CI: 43-53%), with high heterogeneity ( $I^2$   
 237 = 97.9%), indicating substantial variability among the included studies. Sub-group-wise, a  
 238 marginal discrepancy in survival rates was observed between the sexes, with females exhibiting a  
 239 slightly lower survival rate (48%) compared to males (51%), though this difference was not  
 240 statistically significant. However, a significant ethnic disparity was observed, with African non-  
 241 black patients exhibiting a higher survival rate (62%) compared to African black patients (38%).  
 242 Survival rates were also found to be significantly correlated with socioeconomic development.  
 243 Regions exhibiting higher human development index (HDI) levels demonstrated superior  
 244 outcomes, with high HDI regions exhibiting a 60% survival rate, medium HDI regions a 42%  
 245 survival rate, and low HDI regions a 37% survival rate.

246 A similar pattern was observed with the Socio-demographic Index (SDI), where high-  
 247 middle SDI regions exhibited the highest survival rate (62%) and low SDI regions exhibited the  
 248 lowest (34%). Furthermore, it was observed that studies published prior to 2019 indicated a  
 249 higher survival rate (49%) than those conducted from 2019 onwards (44%). Although the impact  
 250 of the COVID-19 pandemic might be considered a contributing factor in this decline, we would  
 251 urge caution in this interpretation. The reported studies were conducted retrospectively, and the  
 252 year of publication may not be a reliable measure of the effect in question. This observed decline  
 253 has been explored and addressed in greater detail later in the paper.


254 Furthermore, considerable variability was observed across African regions, with  
 255 Northern Africa having the highest survival rate (64%) and Western Africa having the lowest  
 256 (32%). Country-specific analyses indicate that Mauritius (73%) and Namibia (70%) recorded the  
 257 highest survival rates, whereas the Gambia (11%) had the lowest rates.  
 258



259  
 260 **Figure 2. Sub-group meta-analysis for 5-year breast cancer survival rates across Africa.** The blue  
 261 box represents the overall survival rate of the respective sub-groups, while the red box indicates the  
 262 pooled overall survival rate. The horizontal lines traversing each box depict the corresponding confidence  
 263 intervals. P<sub>hetero</sub> represents the P value for heterogeneity test while P<sub>subgroup</sub> indicates the P value for the test  
 264 for subgroup analysis. I<sup>2</sup> represents the statistical heterogeneity (%) in the analysis. N/A – not applicable  
 265 due to single study meta-analysis.  
 266

267 We next conducted a cumulative chronological meta-analysis to examine the evolution  
 268 and trajectory of 5-year survival rates. The analysis, which commenced with Tabane et al.,

269 (1977) [68] and concluded with Gngangnon et al., (2024) [83], revealed interesting trends. The  
 270 observed survival rates ranged from 15% to 50% between 1977 and 2024. The P values, which  
 271 were calculated by comparing the observed effect with a previously reported null effect of 47%,  
 272 exhibited considerable variation. Among the included studies, only three demonstrated  
 273 statistically significant results ( $P < 0.05$ ) from this null effect. As the number of studies  
 274 increased, the overall survival rate rose and the confidence intervals narrowed, reflecting  
 275 enhanced precision in the cumulative estimate. However, since the early 2010s, the overall  
 276 survival rate has stabilized around 48-50%, with no discernible or predictable trend in the future.  
 277



278  
 279 **Figure 3. Cumulative meta-analysis for 5-year survival rates in Africa, adding studies in**  
 280 **chronological order.** The blue box represents the overall survival rate of the respective study, while the




281 horizontal lines traversing each box depict the corresponding confidence intervals. Tau, Tau<sup>2</sup>, and I<sup>2</sup>  
282 represent the different measures of statistical heterogeneity in the pooled estimate.

283

### 284 3.2. Meta-regression

285 Meta-regression analyses were performed to evaluate the influence of different factors on  
286 5-year survival rates. Among the continuous factors, mean years of schooling (MYS) and quality  
287 score (QS) of the included studies were both found to have significant influences (P = 0.001 and  
288 0.023, respectively). MYS and QS accounted for 10.85% and 4.80% of the heterogeneity in  
289 survival, respectively. Each additional year of mean schooling was associated with a 2.41% (95%  
290 CI: 0.98-3.84%) increase in 5-year survival. Similarly, each 1-point increase in quality score  
291 was associated with a 1.39% (95% CI: 0.19-2.59%) increase in survival (**Figure 4**).


292



293  
294 **Figure 4. Bubble plots for the relationship between mean years of schooling (MYS) and quality**  
295 **score (QS) of the included studies with the 5-year survival rate of breast cancer patients.** Each point  
296 represents a study, with the size of the points indicating the precision (1/standard error) of the data. The  
297 solid black line represents the regression line, the dashed lines indicate the 95% confidence intervals, and  
298 the dotted lines show the prediction intervals.

299

300 Additional analyses for categorical predictors revealed significant associations for  
301 survival rates with country, patient ethnicity, African continental regions, HDI quartiles, and SDI  
302 quintiles, indicating that survival rates are significantly influenced by these factors. However, no  
303 significant associations were found for patient sex and year of publication (**Figure 5**).




304

305 **Figure 5. Orchard plots for the meta-regression analyses of the 5-year survival rate and categorical**  
 306 **predictors.** The plots show the pooled survival rate (trunk), 95% confidence intervals (branches), and  
 307 prediction intervals (twigs). Bubble sizes indicate precision (1/standard error) of each study, with larger  
 308 points representing higher precision.

### 309 3.3. Publication Bias and Small Study Effects

310 We used the Egger's test to assess funnel plot asymmetry. The test result indicated  
311 significant asymmetry and was considered suggestive of potential publication bias ( $t = -3.15$ ,  $P =$   
312  $0.002$ ). The bias estimate was  $-4.007$  with a standard error (SE) of  $1.271$ . Next, the trim-and-fill  
313 test was performed which included 114 studies, with 26 hypothetical studies added to adjust for  
314 bias (**Figure 6**). The adjusted 5-year survival rate using the random effects model was 62% (95%  
315 CI: 55-67%), with a prediction interval ranging from 10-96%. This adjustment indicates that the  
316 true effect size is likely to be within this broader range, accounting for potential missing studies.  
317



318 **Figure 6. Funnel plots for assessing publication bias in studies reporting breast cancer survival**  
319 **rates.** Standard funnel plot for 88 studies (panel A); contour-enhanced funnel plot for 88 studies (panel  
320 B); Trim-and-fill funnel plot with 26 hypothetical studies (white dots) added to 88 studies (gray dots;  
321 panel C); and Limit meta-analysis funnel plot showing increasing bias with standard error. Gray diamond  
322 shows the adjusted average effect when standard error is zero.  
323

324  
325 The analysis still quantified substantial heterogeneity among the included studies, with a  
326 tau-square ( $\tau^2$ ) value of 1.837 (95% CI: 1.446-2.509). The  $I^2$  statistic was observed to be  
327 extremely high at 98.4% (95% CI: 98.3-98.5%), indicating that nearly all the variability in effect  
328 estimates is due to heterogeneity rather than random chance. The limit meta-analysis, on the  
329 other hand, provided a 5-year survival estimate of 52% (95% CI: 45-59%).

330 Heterogeneity statistics indicated a  $\tau^2$  value of 0.9287, with an  $I^2$  of 97.9% (95% CI: 97.7-  
331 98.1%), reflecting substantial heterogeneity among the studies. Additionally, the test for small-  
332 study effects demonstrated Q-Q' of 430.25 ( $P < 0.0001$ ), suggesting the presence of small-study


333 effects. The residual heterogeneity test produced  $Q' = 3719.79$  ( $P < 0.0001$ ), indicating  
 334 significant residual heterogeneity beyond small-study effects.

335  
 336 **3.4. Comparison with 2018 African Estimates**

337 A previous meta-analysis, which included literature up to October 2018, identified 54  
 338 eligible records from 14 countries [10]. The authors reported a pooled overall 5-year survival rate  
 339 of 53% (95% CI: 46-60%), while our own findings indicated an estimate of 48% (95% CI: 43-  
 340 53%). We conducted a one-sample Z-test for proportions to compare the two estimates and found  
 341 no statistical significance ( $P = 0.071$ ). Nonetheless, given that our estimates indicated a lower  
 342 survival rate than previously reported, we explored the cause for this observation.

343 At first, we postulated that our larger and more diverse data set, comprising 22 countries,  
 344 could have yielded a more precise estimate. To explore this, we subset our data into two groups,  
 345 one part with data from same 14 countries as reported from 2018 meta-analysis and the other part  
 346 with data from 8 new countries (Figure 7). The forest plot demonstrated that the estimate  
 347 derived from the former group remained inferior to the estimates reported by the 2018 study  
 348 (47% vs 53%).

349



350  
 351 **Figure 7. Comparison of our current 5-year survival estimates with the previous 2018 estimates.** A  
 352 territorial map of continental Africa is shown (on the left) with 5-year survival estimates and 95%  
 353 confidence interval from 2018 and 2024. The survival estimates have been rounded off to the nearest  
 354 whole number. Two forest plots are shown (on the right) that were used to estimate the effect of addition  
 355 of eight new countries in our 2024 estimates and the effect of missed/excluded references in the 2018  
 356 estimates.

357  
 358 Subsequently, we cross-referenced the meta-analyzed studies from the previous work and  
 359 those from the present study. We observed that the authors had not included 10 studies that were

360 published before 2018 and met their inclusion criteria, potentially attributable to the limited  
 361 number of databases they searched (Medline, Embase, and Cochrane Library). These studies  
 362 were from Uganda, Gambia, Ghana, Ethiopia, Nigeria, Cameroon, Sudan, and Zimbabwe.  
 363 Inclusion of these 10 studies yielded an estimated 5-year survival rate of 49% (95% CI: 43-56%;  
 364 **Figure 7**), which is in close alignment with our pooled overall survival rate of 48%.


365 This decrease observed in 2018 estimates was expected since the studies not included  
 366 were primarily from low and low-middle SDI countries. In our view, these findings have two  
 367 broader public health ramifications. First, although not significantly different from our estimates,  
 368 the previously reported survival estimates appear to be inflated due to incomplete catch from the  
 369 investigated biomedical databases, highlighting the need for a comprehensive search strategy.  
 370 Second, as observed with our cumulative meta-analysis, the 5-year survival rate has somewhat  
 371 stagnated in Africa. Apart from Ghana, all other countries either observed a modest decrease or  
 372 no change in 5-year survival estimates (**Figure 7**). Burkina Faso and Uganda experienced the  
 373 largest declines, although the one-sample z-test for proportions was not significant ( $P = 0.268$   
 374 and  $0.195$ , respectively).

375

### 376 3.5. Comparison with Global Estimates among Female Patients

377 We also conducted a generic Google Scholar and PubMed search to look for pooled 5-  
 378 year survival rates for breast cancer patients. The search was specifically designed to retrieve  
 379 systematic reviews and meta-analyses published in the last decade that included data from  
 380 multiple countries and had pooled the results based on either regional grouping, WHO regions,  
 381 or at the continent level. Consequently, three such studies were identified for comparison [97-  
 382 99]. Given that these studies reported survival rates exclusively for female patients, they were  
 383 compared with our estimates derived from the female subset only (**Figure 8**).

384



385

386 **Figure 8. Comparison of our current 5-year survival estimates with the previously reported global**  
 387 **estimates.** Forest plot showing the pooled meta-analyzed overall 5-year survival rate with 95%  
 388 confidence interval for female patients with breast cancer across different regions. WHO – World Health  
 389 Organization; PAHO – Pan American Health Organization; WPRO – Western Pacific Region; SEARO –  
 390 South-East Asia Region; EURO – European Region; EMRO – Eastern Mediterranean Region; AFRO –  
 391 African Region; ASEAN – Association of Southeast Asian Nations.

392  
393 A comparative analysis of five-year survival rates for female patients across different  
394 regions revealed significant differences between our 2024 estimates and previously reported  
395 estimates from all regions (one-sample Z test  $P < 0.001$ ), except for the WHO SEARO region  
396 (one-sample Z test  $P = 0.469$ ). In 2017, the WHO WPRO and PAHO regions recorded the  
397 highest global survival rates of 76% and 75%, respectively. Similarly, the WHO EURO and  
398 WHO EMRO regions reported high survival rates of 74% and 71%, respectively.

399 Although the survival rate in the WHO SEARO region was slightly higher than our 2024  
400 estimates, there is clearly room for improvement in both regions. Notably, the estimates from the  
401 WHO AFRO region, based on just four studies, reported a much lower survival rate of 28% in  
402 2017. Upon subsetting and analyzing the results for female patients from WHO AFRO countries  
403 (48 studies; 17 countries), we observed a 5-year survival rate of 38% (95% CI: 32-44%). This  
404 indicates a considerable improvement in the WHO AFRO region's survival rate by 2024. Despite  
405 this progress, the survival rate remains substantially lower than in other WHO regions.

#### 406 407 **4. Discussion**

408 Our meta-analysis of 5-year survival rates for breast cancer patients in Africa offers  
409 comprehensive insights into the current state of clinical outcomes across the continent. We  
410 underscore the considerable disparities in survival rates across different regions and socio-  
411 economic contexts. The overall survival rate of 48% in Africa is markedly lower than those  
412 reported in high-income countries, where survival rates frequently exceed 70-80% [97-99].

413 The sex-stratified analysis indicated no differences in survival rates between male and  
414 female patients, suggesting that both genders encounter considerable challenges in the context of  
415 early diagnostics and timely and effective treatment. In their study, Gómez-Raposo et al., found  
416 that when age is accounted, breast cancer survival rates are similar for both males and females  
417 [100]. Others have also reported similar findings when the cohorts were age-, region-, stage-,  
418 and/or propensity-matched [101-104]. Nonetheless, the marginally higher survival rate observed  
419 in males is interesting, as literature seems to suggest a worse prognosis for male breast cancer  
420 patients. The lower survival rate observed in males has been suggested due to males having a  
421 greater likelihood of being diagnosed at an older age, a higher prevalence of advanced disease  
422 stages, and a tendency to adhere less strictly to treatment regimens [105]. Furthermore, the issue  
423 is compounded by a lack of awareness and the absence of targeted screening programs for male  
424 patients.

425 In the context of our study, data were available for male patients only from nine countries  
426 in Africa. The rarity of male breast cancer surveillance and reporting may have resulted in the  
427 inclusion of smaller, non-representative cohorts, thereby influencing the observed outcomes.  
428 Furthermore, our methodological approach of categorizing studies based on a threshold criterion  
429 ( $\geq 80\%$  of one sex) may also contribute to this observation. Finally, it may also be due to the  
430 absence of triple-negative cases in the male cohort, suggesting that certain aggressive subtypes  
431 are less common among African men [106]. This absence of aggressive difficult-to-manage  
432 phenotypes could influence and contribute to the observed higher survival rates.

433 Furthermore, African black women are more likely to be diagnosed with aggressive  
434 subtypes of breast cancer, such as triple-negative breast cancer (TNBC) [105,107]. TNBC is  
435 characterized by the absence of estrogen, progesterone, and HER2 receptors, which renders it  
436 more challenging to treat and is associated with a poorer prognosis [108-109]. The *ANKLE1*  
437 gene, which confers protection against TNBC, was found to be less prevalent in African

438 American women compared to white women of European descent [110]. Moreover, African  
439 American women with a mutation in the Duffy (*DARC*) gene, which is involved in the  
440 inflammatory response, have an elevated risk of developing TNBC [110].

441 Northern Africa, with its relatively high survival rates, benefits from a more robust  
442 healthcare infrastructure, more efficacious screening programs, and greater public awareness  
443 about breast cancer. It is frequently the case that countries in this region are ranked high on HDI  
444 and SDI evaluations [12-13]. Conversely, the lowest survival rates are observed in Western  
445 Africa, which highlights the necessity for significant investments in healthcare services and  
446 resource allocation. A country-specific analysis revealed significant contrasts, with Mauritius  
447 recording the highest survival rate and Gambia having the lowest. These discrepancies may be  
448 attributable to discrepancies in healthcare systems, the availability of cancer treatment facilities,  
449 and national and international health partnerships and policies.

450 For example, in Mauritius, healthcare is regarded as a fundamental human right, with free  
451 public health services for primary care being made available. Every household is situated within  
452 three miles of a primary care provider, thereby ensuring accessible medical care for all. Active  
453 investments are being made by the Ministry of Health and Wellness to construct a national  
454 cancer hospital, while upgrading facilities at regional hospitals to ensure that cancer treatment is  
455 provided free of charge to all citizens [111]. In contrast, the availability of facilities for breast  
456 cancer screening, diagnosis, and treatment in Gambia is limited. Many of the diagnostic and care  
457 centers are located at distances ranging from 10 to 45 kilometers from patients' residences.  
458 Consequently, nearly half of the Gambian population lacks access to pathologic diagnosis and  
459 surgical management of breast cancer within these distance thresholds [112]. In other countries  
460 with high overall breast cancer survival rates, such as Seychelles and Namibia, which have  
461 higher HDI values, the density of healthcare professionals (HCPs) per 1,000 population exceeds  
462 the United Nations Sustainable Development Goals (SDG) density target of 4.45 HCPs per 1,000  
463 population. Furthermore, these countries maintain healthcare quality ratings above 80% [113].

464 A comparison of the 2024 estimates with the adjusted 2018 estimate and the findings  
465 from our cumulative meta-analysis indicates a stagnation of survival rates around 48-49% over  
466 time. This may be attributed to several factors. The healthcare infrastructure across many African  
467 countries remains underdeveloped, with the availability of essential diagnostic tools and  
468 advanced treatment options remaining constrained, particularly in rural and low-resource settings  
469 [114]. This inadequacy results in delayed diagnoses and suboptimal treatment outcomes.  
470 Socioeconomic and cultural mistrust in Western medicine, in conjunction with pervasive poverty  
471 and economic disparities, impede the capacity of patients to access essential healthcare services  
472 at a reasonable cost [115-116]. Traditional beliefs and stigma associated with cancer can act as a  
473 deterrent for individuals seeking medical care [117-118]. Despite the importance of efforts to  
474 raise awareness and educate the population about the significance of early detection and  
475 treatment, initiatives have thus far proven inadequate in terms of both scope and impact.

476 Systemic issues, including political instability and corruption, serve to further exacerbate  
477 these challenges, impeding the implementation of cancer care programs [119]. Ultimately,  
478 inadequate financial resources have an adverse ripple effect throughout the healthcare system,  
479 from the unavailability of essential medications to the lack of sufficient training for HCPs,  
480 perpetuating a vicious cycle of inadequate care and poor patient outcomes. Our observations also  
481 highlight that sustained improvements in particular regions or countries are insufficient to  
482 significantly alter the overall continental survival rate. The considerable heterogeneity observed

483 in the studies highlights the uneven distribution of healthcare resources and the variable quality  
484 of care across different countries and regions.

485 Another notable finding was the positive correlation between mean years of schooling  
486 (MYS) and breast cancer survival rates. Education plays a crucial role in enhancing health  
487 outcomes by fostering health literacy, which provides for greater awareness of breast cancer  
488 symptoms, the significance of early detection, and adherence to treatment regimens. Higher  
489 levels of educational attainment afford patients the ability to navigate the healthcare system with  
490 greater confidence and to make more informed decisions regarding their care. Furthermore, the  
491 analysis underscores the influence of study quality on the reported survival rates, indicating that  
492 higher-quality studies are associated with more favorable survival outcomes. This highlights the  
493 necessity of rigorous study design and adherence to methodological standards to produce reliable  
494 and accurate data. The quality of the studies included in the meta-analysis is reflective of the  
495 variability in healthcare infrastructure, research funding, and expertise across different regions.

496 It is hence necessary to improve the caliber of research conducted in resource-limited  
497 settings to generate evidence-based unbiased data and subsequently inform policy and practice.  
498 The observed heterogeneity in survival rates is significantly influenced by region, country, race,  
499 SDI, and HDI. This indicates that geographical and socio-economic factors exert a more  
500 pronounced influence on breast cancer outcomes in Africa than temporal trends or gender or  
501 ethnicity. The evidence of significant publication bias, as indicated by Egger's test, suggests that  
502 the reported survival rates may be overestimated due to the under-reporting of smaller studies  
503 with less favorable outcomes.

504

#### 505 **4.1. Limitations**

506 While we followed a comprehensive protocol, there are several methodological  
507 limitations that warrant consideration. The substantial heterogeneity among the included studies  
508 indicates significant variability in survival rates, likely due to differences in study design,  
509 population characteristics, and healthcare systems, complicating the generalization of results  
510 across the continent. The presence of publication bias suggests that smaller studies might be  
511 under-represented, potentially skewing the overall survival rate estimate despite adjustments  
512 using the trim and fill method. Additionally, the analysis included studies from only 22 out of 54  
513 African countries, limiting the representativeness of the findings and potentially overlooking  
514 variations in survival rates in countries with no available data.

515 The reliance on published studies means that the quality and accuracy of the data are  
516 contingent on the methodologies and reporting standards of the original research, introducing  
517 inconsistencies. For instance, our approach for classification of studies based on patient sex does  
518 not fully account for the nuanced effects of sex on breast cancer outcomes and could lead to an  
519 over-estimation or under-estimation of survival rates for each sex. Additionally, while this  
520 threshold ensures the majority sex group's characteristics predominantly drive the outcomes, it  
521 highlights the necessity for further research to comprehensively disaggregate, record, and report  
522 data by sex. Another crucial disadvantage of reporting inconsistencies is that tumor  
523 characteristics (staging, TNM classification, histological classification, localization, primary  
524 tumor/metastasis) and clinically relevant parameters (patient age, treatment modality, follow-up  
525 duration, quality of life outcomes) cannot be compared and pooled together.

526 Such limitations have been reported by previous global meta-analytical studies as well  
527 where authors reported that data from low- and middle-income countries such as those in Africa  
528 and Asia had >50% of patients with unknown breast cancer stages to report [6]. Furthermore,



529 assessment of tumor staging should be done using both clinical and radiological methods.  
530 However, a meta-analysis for Sub-Saharan African countries noted that < 25% of the studies  
531 reported the staging methods used with a few studies relying only on clinical assessment for  
532 staging [120]. Finally, socio-economic factors such as income and access to healthcare, which  
533 significantly impact patient outcomes, were not fully accounted for in the analysis. Addressing  
534 these limitations in future studies will enhance the accuracy and reliability of the findings,  
535 contributing to better-informed healthcare policies and interventions.

536

#### 537 **4.2. Recommendations based on current estimates**

538 We reiterate the longstanding and urgent necessity of implementing targeted healthcare  
539 policies to address the considerable regional disparities that are prevalent among African  
540 countries. The observed correlation between higher survival rates and countries with a high HDI,  
541 MYS, and SDI underscores the pivotal role of robust healthcare infrastructure, education, and  
542 socio-economic development in enhancing cancer care. It is incumbent upon policymakers to  
543 prioritize the allocation of resources to regions with the lowest survival rates, such as Western  
544 Africa, and to invest in the development of healthcare facilities, diagnostic tools, and treatment  
545 centers. Furthermore, it is crucial to enhance the training of HCPs in oncology, molecular  
546 diagnostics, and palliative care. Implementing culturally sensitive public health campaigns,  
547 adopting universal healthcare, and expanding insurance coverage to include cancer treatment are  
548 essential steps.

549 The considerable heterogeneity and publication bias identified in our meta-analysis  
550 underscores the need for more comprehensive and high-quality record keeping and research,  
551 including the establishment of national cancer registries. International collaboration and  
552 partnerships with global health organizations can facilitate the transfer of knowledge and the  
553 allocation of funding for improvements in cancer care. There is a need to develop and implement  
554 an Africa-wide public health framework for the development of targeted strategies that address  
555 the specific needs and challenges of different regions and populations in Africa.

556

#### 557 **5. Conclusions**

558 Our findings highlight the significant regional disparities in breast cancer survival rates  
559 across the African continent, reinforcing the urgent and sustained need for targeted health  
560 interventions. The substantial heterogeneity among studies reflects the variability in the quality  
561 of and access to health care across countries. The higher survival rates in countries with high  
562 HDI and SDI values underscore the importance of robust health systems and socioeconomic  
563 development in improving survival. Gender differences in survival were found not to be a  
564 covariate, highlighting the importance of controlling for other clinical and socio-demographic  
565 factors. These findings provide a roadmap for developing effective cancer screening programs  
566 and health policies, including implementation of uniform reporting standards and establishment  
567 of national cancer registries, to improve breast cancer surveillance, monitoring, and survival  
568 rates across the continent.

569

#### 570 **6. Declarations**

571 **a. Conflicts of interest** – None to declare.

572

573 **b. Funding** – None to declare.

574

- 575 **c. Ethical approval** – Not applicable.  
576
- 577 **d. Data Availability** – All data generated is presented in the manuscript and appendices.  
578 Clarifications on methodology and requests for the R code can be directed to the  
579 corresponding authors.  
580
- 581 **e. Informed Consent** – Not applicable.  
582
- 583 **f. Acknowledgements** – None to declare.  
584
- 585 **g. Author contributions** – ABP and NJ conceptualized the present study. Data curation,  
586 collection, and screening was done by ABP, EKK, AGB, JK, AAE, BS, IN, and BOO  
587 with inputs and validation from NJ. Methodology, investigations, visualizations, and  
588 formal analysis were done by EKK and NJ. Software and code were maintained by EKK  
589 and NJ. Project administration and supervision was done by ABP and NJ. Data validation  
590 was done by EKK and NJ. The original draft was prepared by EKK, JK, ABP, and NJ  
591 while all authors were involved in revising the manuscript. All authors have read the  
592 manuscript and agreed on its contents for publication.  
593

## 594 7. References

- 595 1. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. *Br J Radiol.*  
596 2022 Feb 1;95(1130):20211033. doi: 10.1259/bjr.20211033. Epub 2021 Dec 14. PMID:  
597 34905391; PMCID: PMC8822551.
- 598 2. Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, et al.  
599 The Lancet Breast Cancer Commission. *Lancet.* 2024 May 11;403(10439):1895-1950. doi:  
600 10.1016/S0140-6736(24)00747-5. Epub 2024 Apr 15. PMID: 38636533.
- 601 3. Sha R, Kong XM, Li XY, Wang YB. Global burden of breast cancer and attributable risk factors  
602 in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease  
603 Study 2021. *Biomark Res.* 2024 Aug 26;12(1):87. doi: 10.1186/s40364-024-00631-8. PMID:  
604 39183342; PMCID: PMC11346191.
- 605 4. Testa U, Castelli G, Pelosi E. Breast Cancer: A Molecularly Heterogenous Disease Needing  
606 Subtype-Specific Treatments. *Med Sci (Basel).* 2020 Mar 23;8(1):18. doi:  
607 10.3390/medsci8010018. PMID: 32210163; PMCID: PMC7151639.
- 608 5. Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular  
609 subtypes of breast cancer. *Am J Physiol Cell Physiol.* 2021 Aug 1;321(2):C343-C354. doi:  
610 10.1152/ajpcell.00109.2021. Epub 2021 Jun 30. PMID: 34191627; PMCID: PMC8424677.
- 611 6. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, Mafra A, Shah R, Giusti F, Vignat J, Znaor A,  
612 et al. Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-  
613 Analysis. *JAMA Oncol.* 2024 Jan 1;10(1):71-78. doi: 10.1001/jamaoncol.2023.4837. PMID:  
614 37943547; PMCID: PMC10636649.
- 615 7. Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for  
616 breast cancer in low-income and upper middle-income countries: a modelling study. *Lancet Glob*  
617 *Health.* 2018 Aug;6(8):e885-e893. doi: 10.1016/S2214-109X(18)30257-2. PMID: 30012269;  
618 PMCID: PMC6214657.

- 619 8. Anyigba CA, Awandare GA, Paemka L. Breast cancer in sub-Saharan Africa: The current state  
620 and uncertain future. *Exp Biol Med* (Maywood). 2021 Jun;246(12):1377-1387. doi:  
621 10.1177/15353702211006047. Epub 2021 Apr 29. PMID: 33926257; PMCID: PMC8243219.
- 622 9. Arnold M, Morgan E, Runggay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, et al.  
623 Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast*. 2022  
624 Dec;66:15-23. doi: 10.1016/j.breast.2022.08.010. Epub 2022 Sep 2. PMID: 36084384; PMCID:  
625 PMC9465273.
- 626 10. Ssentongo P, Lewcun JA, Candela X, Ssentongo AE, Kwon EG, Ba DM, Oh JS, Amponsah-Manu  
627 F, et al. Regional, racial, gender, and tumor biology disparities in breast cancer survival rates in  
628 Africa: A systematic review and meta-analysis. *PLoS One*. 2019 Nov 21;14(11):e0225039. doi:  
629 10.1371/journal.pone.0225039. PMID: 31751359; PMCID: PMC6872165.
- 630 11. Lakens D, Hilgard J, Staaks J. On the reproducibility of meta-analyses: six practical  
631 recommendations. *BMC Psychol*. 2016 May 31;4(1):24. doi: 10.1186/s40359-016-0126-3. PMID:  
632 27241618; PMCID: PMC4886411.
- 633 12. United Nations Development Programme (UNDP). Human Development Reports: Human  
634 Development Index (HDI). 2024 [online]. Available from [https://hdr.undp.org/data-center/human-](https://hdr.undp.org/data-center/human-development-index#/indicies/HDI)  
635 [development-index#/indicies/HDI](https://hdr.undp.org/data-center/human-development-index#/indicies/HDI) (accessed 1st November 2024).
- 636 13. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD  
637 2021) Socio-Demographic Index (SDI) 1950–2021. Seattle, United States of America: Institute  
638 for Health Metrics and Evaluation (IHME), 2024 [online]. Available from  
639 [https://ghdx.healthdata.org/record/global-burden-disease-study-2021-gbd-2021-socio-](https://ghdx.healthdata.org/record/global-burden-disease-study-2021-gbd-2021-socio-demographic-index-sdi-1950%E2%80%932021)  
640 [demographic-index-sdi-1950%E2%80%932021](https://ghdx.healthdata.org/record/global-burden-disease-study-2021-gbd-2021-socio-demographic-index-sdi-1950%E2%80%932021) (Accessed 1st November 2024).
- 641 14. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating  
642 summary time-to-event data into meta-analysis. *Trials*. 2007 Jun 7;8:16. doi: 10.1186/1745-6215-  
643 8-16. PMID: 17555582; PMCID: PMC1920534.
- 644 15. Limenih MA, Mekonnen EG, Birhanu F, Jima BR, Sisay BG, Kassahun EA, Hassen HY. Survival  
645 Patterns Among Patients With Breast Cancer in Sub-Saharan Africa: A Systematic Review and  
646 Meta-Analysis. *JAMA Netw Open*. 2024 May 1;7(5):e2410260. doi:  
647 10.1001/jamanetworkopen.2024.10260. PMID: 38743426; PMCID: PMC11094564.
- 648 16. Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, Viechtbauer W,  
649 Simmonds M. A comparison of heterogeneity variance estimators in simulated random-effects  
650 meta-analyses. *Res Synth Methods*. 2019 Mar;10(1):83-98. doi: 10.1002/jrsm.1316. Epub 2018  
651 Sep 6. PMID: 30067315.
- 652 17. Tanriver-Ayder E, Faes C, van de Castele T, McCann SK, Macleod MR. Comparison of  
653 commonly used methods in random effects meta-analysis: application to preclinical data in drug  
654 discovery research. *BMJ Open Sci*. 2021 Feb 25;5(1):e100074. doi: 10.1136/bmjos-2020-100074.  
655 PMID: 35047696; PMCID: PMC8647574.
- 656 18. Galukande M, Wabinga H, Mirembe F. Breast cancer survival experiences at a tertiary hospital in  
657 sub-Saharan Africa: a cohort study. *World J Surg Oncol*. 2015 Jul 19;13:220. doi:  
658 10.1186/s12957-015-0632-4. PMID: 26187151; PMCID: PMC4506617.
- 659 19. Gakwaya A, Kigula-Mugambe JB, Kavuma A, Luwaga A, Fualal J, Jombwe J, Galukande M,  
660 Kanyike D. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. *Br J Cancer*.  
661 2008 Jul 8;99(1):63-7. doi: 10.1038/sj.bjc.6604435. Epub 2008 Jun 24. PMID: 18577991;  
662 PMCID: PMC2453032.
- 663 20. Thomas AS, Kidwell KM, Oppong JK, Adjei EK, Osei-Bonsu E, Boahene A, Jiggae E, Gyan K,  
664 Merajver SD. Breast Cancer in Ghana: Demonstrating the Need for Population-Based Cancer

- 665 Registries in Low- and Middle-Income Countries. *J Glob Oncol.* 2017 Dec;3(6):765-772. doi:  
666 10.1200/JGO.2016.006098. Epub 2017 Mar 27. PMID: 29244986; PMCID: PMC5735963.
- 667 21. Anele AA, Bowling M, Eckert GJ, Gonzalez E, Kipfer H, Sauder C. Treatment of Breast Cancer:  
668 Imo State Nigeria Versus Indiana, USA Women - Comparative Analytic Study. *J West Afr Coll*  
669 *Surg.* 2014 Oct-Dec;4(4):39-69. PMID: 27182510; PMCID: PMC4866729.
- 670 22. Cubasch H, Dickens C, Joffe M, Duarte R, Murugan N, Tsai Chih M, Moodley K, Sharma V,  
671 Ayeni O, Jacobson JS, Neugut AI, McCormack V, Ruff P. Breast cancer survival in Soweto,  
672 Johannesburg, South Africa: A receptor-defined cohort of women diagnosed from 2009 to 11.  
673 *Cancer Epidemiol.* 2018 Feb;52:120-127. doi: 10.1016/j.canep.2017.12.007. Epub 2018 Jan 4.  
674 PMID: 29306221; PMCID: PMC6127863.
- 675 23. Eber-Schulz P, Tariku W, Reibold C, Addissie A, Wickenhauser C, Fathke C, Hauptmann S, Jemal  
676 A, Thomssen C, Kantelhardt EJ. Survival of breast cancer patients in rural Ethiopia. *Breast*  
677 *Cancer Res Treat.* 2018 Jul;170(1):111-118. doi: 10.1007/s10549-018-4724-z. Epub 2018 Feb 26.  
678 PMID: 29479644.
- 679 24. Kantelhardt EJ, Zerche P, Mathewos A, Trocchi P, Addissie A, Aynalem A, Wondemagegnehu T,  
680 Ersumo T, et al. Breast cancer survival in Ethiopia: a cohort study of 1,070 women. *Int J Cancer.*  
681 2014 Aug 1;135(3):702-9. doi: 10.1002/ijc.28691. Epub 2014 Jan 10. PMID: 24375396.
- 682 25. Makanjuola SB, Popoola AO, Oludara MA. Radiation therapy: a major factor in the five-year  
683 survival analysis of women with breast cancer in Lagos, Nigeria. *Radiother Oncol.* 2014  
684 May;111(2):321-6. doi: 10.1016/j.radonc.2014.03.013. Epub 2014 Apr 17. PMID: 24746579.
- 685 26. Kene TS, Odigie VI, Yusufu LM, Yusuf BO, Shehu SM, Kase JT. Pattern of presentation and  
686 survival of breast cancer in a teaching hospital in north Western Nigeria. *Oman Med J.* 2010  
687 Apr;25(2):104-7. doi: 10.5001/omj.2010.29. PMID: 22125710; PMCID: PMC3215495.
- 688 27. Ikpatt OF, Ndoma-Egba R, Collan Y. Influence of age and prognosis of breast cancer in Nigeria.  
689 *East Afr Med J.* 2002 Dec;79(12):651-7. doi: 10.4314/eamj.v79i12.8673. PMID: 12678449.
- 690 28. Souad H, Zahia F, Abdelhak L, Karima S, Dalila S, Noureddine A. Descriptive study of triple  
691 negative breast cancer in Eastern Algeria. *Pan Afr Med J.* 2018 Jan 18;29:45. doi:  
692 10.11604/pamj.2018.29.45.12523. PMID: 29875927; PMCID: PMC5987100.
- 693 29. Ismail A, El-Awady R, Mohamed G, Hussein M, Ramadan SS. Prognostic Significance of Serum  
694 Vitamin D Levels in Egyptian Females with Breast Cancer. *Asian Pac J Cancer Prev.* 2018 Feb  
695 26;19(2):571-576. doi: 10.22034/APJCP.2018.19.2.571. PMID: 29481024; PMCID:  
696 PMC5980952.
- 697 30. Bogan D, Meile L, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. The role  
698 of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt:  
699 possible link to disease early lesion. *BMC Cancer.* 2017 May 12;17(1):329. doi: 10.1186/s12885-  
700 017-3283-8. PMID: 28499366; PMCID: PMC5429567.
- 701 31. Aiad HA, Kandil MA, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA,  
702 Aleskandarany MA. The prognostic and predictive significance of PARP-1 in locally advanced  
703 breast cancer of Egyptian patients receiving neoadjuvant chemotherapy. *Appl Immunohistochem*  
704 *Mol Morphol.* 2015 Sep;23(8):571-9. doi: 10.1097/PAI.000000000000124. PMID: 25611238.
- 705 32. Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H, Moneer MM.  
706 Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic  
707 triple negative breast cancer. *Clin Biochem.* 2009 Sep;42(13-14):1420-6. doi:  
708 10.1016/j.clinbiochem.2009.06.022. Epub 2009 Jul 2. PMID: 19576877.
- 709 33. Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, Abodeef WT. Survival effects of  
710 cyclooxygenase-2 and 12-lipoxygenase in Egyptian women with operable breast cancer. *Indian J*  
711 *Cancer.* 2009 Jan-Mar;46(1):54-60. doi: 10.4103/0019-509x.48597. PMID: 19282568.

- 712 34. Slaoui M, Mouh FZ, Ghanname I, Razine R, El Mzibri M, Amrani M. Outcome of Breast Cancer  
713 in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and  
714 Treatment: A Comparative Study of 716 Cases in a Single Institution. *PLoS One*. 2016 Oct  
715 19;11(10):e0164841. doi: 10.1371/journal.pone.0164841. PMID: 27760178; PMCID:  
716 PMC5070817.
- 717 35. Ermiah E, Buhmeida A, Khaled BR, Abdalla F, Salem N, Pyrhönen S, Collan Y. Prognostic value  
718 of bcl-2 expression among women with breast cancer in Libya. *Tumour Biol*. 2013  
719 Jun;34(3):1569-78. doi: 10.1007/s13277-013-0687-1. Epub 2013 Feb 16. PMID: 23417836.
- 720 36. Ngowa JDK, Kasia JM, Yomi J, Nana AN, Ngassam A, Domkam I, Sando Z, Ndom P. Breast  
721 Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaoundé General  
722 Hospital. *Advances in Breast Cancer Research*. 2015;4(2):44-52. doi: 10.4236/abcr.2015.42005.
- 723 37. Abdalla FB, Markus R, Buhmeida A, Boder J, Syrjänen K, Collan Y. Estrogen receptor,  
724 progesterone receptor, and nuclear size features in female breast cancer in Libya: correlation with  
725 clinical features and survival. *Anticancer Res*. 2012 Aug;32(8):3485-93. PMID: 22843935.
- 726 38. Ben Ahmed S, Aloulou S, Bibi M, Landolsi A, Nouira M, Ben Fatma L, Kallel L, Gharbi O,  
727 Korbi S, Khaïri H, Kraïem C. Pronostic du cancer du sein chez les femmes tunisiennes: analyse  
728 d'une série hospitalière de 729 patientes [Breast cancer prognosis in Tunisian women: analysis of  
729 a hospital series of 729 patients]. *Sante Publique*. 2002 Sep;14(3):231-41. French. PMID:  
730 12564048.
- 731 39. Samaka RM, Younes SF. Androgen Receptor Expression in Breast Carcinoma of Egyptian  
732 Patients. *J Clin Diagn Res*. 2016 Nov;10(11):EC17-EC21. doi: 10.7860/JCDR/2016/23364.8919.  
733 Epub 2016 Nov 1. PMID: 28050375; PMCID: PMC5198328.
- 734 40. Derkaoui T, Bakkach J, Mansouri M, Loudiyi A, Fihri M, Alaoui FZ, Barakat A, El Yemlahi B, et  
735 al. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features.  
736 *BMC Womens Health*. 2016 Oct 22;16(1):68. doi: 10.1186/s12905-016-0346-y. PMID:  
737 27770782; PMCID: PMC5075166.
- 738 41. Traore B, Toure A, Sy T, Dieng MM, Conde M, Dem A, Keita N, Sylla BS. Five-year prognosis  
739 of breast cancer patients in Conakry Hospital University (West Africa). *J Clin Oncol*.  
740 2015;33(15\_Suppl):e12065. doi: 10.1200/jco.2015.33.15\_suppl.e12065.
- 741 42. Ayoade BA, Agboola AJ, Olatunji AA, Tade AO, Salami BA, Adekoya AO. Clinical  
742 characteristics and survival outcome of breast cancer in southwest Nigerian women. *J Afr Cancer*.  
743 2014;6:79-84. doi: 10.1007/s12558-014-0311-8.
- 744 43. Zeeneldin AA, Ramadan M, Elmashad N, Fakhr I, Diaa A, Mosaad E. Breast cancer laterality  
745 among Egyptian patients and its association with treatments and survival. *J Egypt Natl Canc Inst*.  
746 2013 Dec;25(4):199-207. doi: 10.1016/j.jnci.2013.09.003. Epub 2013 Oct 25. PMID: 24207092.
- 747 44. Mohammad MA, Zeeneldin AA, Abd Elmageed ZY, Khalil EH, Mahdy SM, Sharada HM,  
748 Sharawy SK, Abdel-Wahab AH. Clinical relevance of cyclooxygenase-2 and matrix  
749 metalloproteinases (MMP-2 and MT1-MMP) in human breast cancer tissue. *Mol Cell Biochem*.  
750 2012 Jul;366(1-2):269-75. doi: 10.1007/s11010-012-1305-z. Epub 2012 Apr 18. PMID:  
751 22527932.
- 752 45. Kantelhardt EJ, Zerche P, Trocchi P, Mathios A, Reeler A, Tufa G, Yonas B, Stang A, et al. Breast  
753 cancer in Sub-Saharan Africa: 1,000 patients with primary breast cancer in Addis Ababa followed  
754 for up to 5 years. *J Clin Oncol*. 2012;30(15\_Suppl):580. doi: 10.1200/jco.2012.30.15\_suppl.580.
- 755 46. Seedhom AE, Kamal NN. Factors affecting survival of women diagnosed with breast cancer in  
756 El-Minia Governorate, Egypt. *Int J Prev Med*. 2011 Jul;2(3):131-8. PMID: 21811654; PMCID:  
757 PMC3143525.

- 758 47. El Mongy M, El Hossieny H, Haggag F, Fathy R. Clinico-pathological study and treatment results  
759 of 1009 operable breast cancer cases: Experience of NCI Cairo University, Egypt. *Chin. -Ger. J.*  
760 *Clin. Oncol.* 2010; 9:409–415. doi: 10.1007/s10330-010-0614-5.
- 761 48. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO,  
762 et al. Cancer survival in Africa, Asia, and Central America: a population-based study. *Lancet*  
763 *Oncol.* 2010 Feb;11(2):165-73. doi: 10.1016/S1470-2045(09)70335-3. Epub 2009 Dec 10. PMID:  
764 20005175.
- 765 49. Kaabia O, Amine G, Nawel A, Feten H, Afraa B. Male Breast Cancer in Tunisia: Epidemiological  
766 and Clinical Features & Prognosis Factors. *International Journal of Gynecological Cancer.*  
767 2017;27(November Suppl 4):631 (ESGO7-1121). doi: 10.1097/01.IGC.0000527296.86225.87.
- 768 50. Alaoui Slimani K, Debbagh A, Sbitti Y, Errihani H, Ichou M. Cancer du sein chez l'homme au  
769 Maroc : épidémiologie et facteurs pronostiques. À propos de 140 cas [Male breast cancer in  
770 Morocco: Epidemiology and prognostic factors. A report of 140 cases]. *Gynecol Obstet Fertil.*  
771 2016 Nov;44(11):636-640. French. doi: 10.1016/j.gyobfe.2016.08.009. Epub 2016 Sep 23.  
772 PMID: 27671207.
- 773 51. El-Beshbeshi W, Abo-Elnaga EM. Male breast cancer: 10-year experience at mansoura university  
774 hospital in egypt. *Cancer Biol Med.* 2012 Mar;9(1):23-8. doi: 10.3969/j.issn.2095-  
775 3941.2012.01.004. PMID: 23691450; PMCID: PMC3643641.
- 776 52. El-Baradie M, Salama A, Khorshid O, Ismail H, Attia G, Abeer A. Egyptian male breast  
777 carcinoma: patients' hormonal profile, management and outcome. *Chin.-Ger. J. Clin. Oncol.*  
778 2012; 11:89–98. doi: 10.1007/s10330-011-0918-0.
- 779 53. Bourhafour M, Belbaraka R, Souadka A, M'rabti H, Tijami F, Errihani H. Male breast cancer: a  
780 report of 127 cases at a Moroccan institution. *BMC Res Notes.* 2011 Jun 29;4:219. doi:  
781 10.1186/1756-0500-4-219. PMID: 21714875; PMCID: PMC3143075.
- 782 54. Ihekwa FN. The management of male breast cancer in Nigerians. *Postgrad Med J.* 1993  
783 Jul;69(813):562-5. doi: 10.1136/pgmj.69.813.562. PMID: 8415345; PMCID: PMC2399872.
- 784 55. Bouzid N, Lahmar R, Tebra S, Bouaouina N. Cancer du sein chez la femme jeune de moins de 35  
785 ans en Tunisie: étude rétrospective à propos de 124 cas [Breast cancer in woman younger than 35  
786 years in Tunisia: retrospective study about 124 cases]. *Gynecol Obstet Fertil.* 2013 Jun;41(6):356-  
787 60. French. doi: 10.1016/j.gyobfe.2013.05.002. Epub 2013 Jun 7. PMID: 23747138.
- 788 56. Khanfir A, Frikha M, Kallel F, Meziou M, Trabelsi K, Boudawara T, Mnif J, Daoud J. Le cancer  
789 du sein de la femme jeune dans le sud tunisien [Breast cancer in young women in the south of  
790 Tunisia]. *Cancer Radiother.* 2006 Dec;10(8):565-71. French. doi: 10.1016/j.canrad.2006.09.115.  
791 Epub 2006 Nov 30. PMID: 17140835.
- 792 57. Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani S, Barakat A, Ghailani  
793 Nourouti N, et al. Clinicopathologic and prognostic features of breast cancer in young women: a  
794 series from North of Morocco. *BMC Womens Health.* 2017 Nov 9;17(1):106. doi:  
795 10.1186/s12905-017-0456-1. PMID: 29121898; PMCID: PMC5680801.
- 796 58. Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M. Om.breast cancer in  
797 very young women aged 25 year-old or below in the center of Tunisia and review of the literature.  
798 *Pathol Oncol Res.* 2015 Jul;21(3):553-61. doi: 10.1007/s12253-015-9944-5. Epub 2015 May 12.  
799 PMID: 25962349.
- 800 59. Kallel M, Elloumi F, Khabir A, Ghorbal L, Chaabouni S, Amouri H, Frikha M, Daoud J. Breast  
801 cancer in young women in southern Tunisia: Anatomical study and clinical prognostic factors:  
802 About a series of 83 patients. *Rep Pract Oncol Radiother.* 2015 May-Jun;20(3):155-60. doi:  
803 10.1016/j.rpor.2015.01.007. Epub 2015 Mar 6. PMID: 25949218; PMCID: PMC4418592.

- 804 60. Khelifi O, Zeghal D, Jeridi S, Ben Hmid R, Zouari F, Mahjoub S. Young women's breast cancer.  
805 International Journal of Gynecology and Obstetrics. 2012;119(Suppl\_3):S630 (M307). doi:  
806 10.1016/S0020-7292(12)61498-2.
- 807 61. Basro S, Apffelstaedt JP. Breast cancer in young women in a limited-resource environment. World  
808 J Surg. 2010 Jul;34(7):1427-33. doi: 10.1007/s00268-009-0299-5. PMID: 19997919.
- 809 62. Parag Y, Buccimazza I. How long are elderly patients followed up with mammography after the  
810 diagnosis of breast cancer? A single-centre experience in a developing country. S Afr Med J. 2016  
811 Jun 17;106(7):721-3. doi: 10.7196/SAMJ.2016.v106i7.10405. PMID: 27384369.
- 812 63. Zongo N, Ouédraogo S, Korsaga-Somé N, Somé OR, Go N, Ouangré E, Zida M, Bonkoungou G,  
813 et al. Male breast cancer: diagnosis stages, treatment and survival in a country with limited  
814 resources (Burkina Faso). World J Surg Oncol. 2018 Jan 11;16(1):4. doi: 10.1186/s12957-017-  
815 1297-y. PMID: 29325566; PMCID: PMC5765600.
- 816 64. Ahmed A, Ukwenya Y, Abdullahi A, Muhammad I. Management and outcomes of male breast  
817 cancer in zaria, Nigeria. Int J Breast Cancer. 2012;2012:845143. doi: 10.1155/2012/845143. Epub  
818 2012 Sep 6. PMID: 22991670; PMCID: PMC3443591.
- 819 65. Elshafiey MM, Zeeneldin AA, Elsebai HI, Moneer M, Mohamed DB, Gouda I, Attia AA.  
820 Epidemiology and management of breast carcinoma in Egyptian males: experience of a single  
821 Cancer Institute. J Egypt Natl Canc Inst. 2011 Sep;23(3):115-22. doi: 10.1016/j.jnci.2011.10.001.  
822 Epub 2011 Nov 18. PMID: 22776816.
- 823 66. El-Habbash MM, Alwindi AA. Male breast cancer in Tripoli, Libya. Saudi Med J. 2009  
824 Aug;30(8):1060-2. PMID: 19668888.
- 825 67. Ben Dhiab T, Bouzid T, Gamoudi A, Ben Hassouna J, Khomsi F, Boussen H, Benna F, El May A,  
826 et al. Le cancer du sein chez l'homme: à propos de 123 cas colligés à l'institut Salah-Azaïz de  
827 Tunis de 1979 à 1999 [Male breast cancer: about 123 cases collected at the Institute Salah-Azaiz  
828 of Tunis from 1979 to 1999]. Bull Cancer. 2005 Mar;92(3):281-5. French. PMID: 15820923.
- 829 68. Tabbane F, Muenz L, Jaziri M, Cammoun M, Belhassen S, Mourali N. Clinical and prognostic  
830 features of a rapidly progressing breast cancer in Tunisia. Cancer. 1977 Jul;40(1):376-82. doi:  
831 10.1002/1097-0142(197707)40:1<376::aid-cnrcr2820400153>3.0.co;2-y. PMID: 880564.
- 832 69. Mabula JB, Mchembe MD, Chalya PL, Giiti G, Chandika AB, Rambau P, Masalu N, Gilyomai  
833 JM. Stage at diagnosis, clinicopathological and treatment patterns of breast cancer at Bugando  
834 Medical Centre in north-western Tanzania. Tanzan J Health Res. 2012 Oct;14(4):269-79. PMID:  
835 26591725.
- 836 70. Ben Gobrane H, Fakhfakh R, Rahal K, Ben Ayed F, Mâalej M, Ben Abdallah M, Achour N, Hsairi  
837 M. Pronostic du cancer du sein à l'Institut de Carcinologie Salah Azaïez de Tunis [Breast cancer  
838 prognosis in Salah Azaiez Institute of Cancer, Tunis]. East Mediterr Health J. 2007 Mar-  
839 Apr;13(2):309-18. French. PMID: 17684853.
- 840 71. Weiner CM, Mathewos A, Addissie A, Ayele W, Aynalem A, Wondemagegnehu T, Wienke A,  
841 Jemal A, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort  
842 study of 573 women. Breast. 2018 Dec;42:23-30. doi: 10.1016/j.breast.2018.08.095. Epub 2018  
843 Aug 7. PMID: 30149234.
- 844 72. Ersumo T, Tamrat G, Solomon B, Gero T. Breast cancer in a private medical services center: a 10-  
845 year experience. Ethiopian Medical Journal. 2018;56(3):211-218. Available from  
846 <https://emjema.org/index.php/EMJ/article/view/857> (accessed 29th November 2024).
- 847 73. Shiferaw WS, Aynalem YA, Akalu TY, Demelew TM. Incidence and Predictors of Recurrence  
848 among Breast Cancer Patients in Black Lion Specialized Hospital Adult Oncology Unit, Addis  
849 Ababa, Ethiopia: Retrospective Follow-up Study with Survival Analysis. J Cancer Prev. 2020 Jun  
850 30;25(2):111-118. doi: 10.15430/JCP.2020.25.2.111. PMID: 32647652; PMCID: PMC7337003.

- 851 74. Fouhi ME, Mesfioui A, Benider A. Male breast cancer: a report of 25 cases. *Pan Afr Med J.* 2020  
852 Dec 15;37:343. doi: 10.11604/pamj.2020.37.343.23004. PMID: 33738031; PMCID:  
853 PMC7934185.
- 854 75. Abdalla Elhassan SI. The five-year survival rate of breast cancer at Radiation and Isotopes Centre  
855 Khartoum, Sudan. *Heliyon.* 2020 Aug 20;6(8):e04615. doi: 10.1016/j.heliyon.2020.e04615.  
856 PMID: 32904288; PMCID: PMC7452576.
- 857 76. Zingue S, Atenguena EO, Zingue LL, Tueche AB, Njamen D, Nkoum AB, Ndom P.  
858 Epidemiological and clinical profile, and survival of patients followed for breast cancer between  
859 2010 and 2015 at the Yaounde General Hospital, Cameroon. *Pan Afr Med J.* 2021 Jul 7;39:182.  
860 doi: 10.11604/pamj.2021.39.182.26866. PMID: 34466203; PMCID: PMC8378266.
- 861 77. Ali-Gombe M, Mustapha MI, Folasire A, Ntekim A, Campbell OB. Pattern of survival of breast  
862 cancer patients in a tertiary hospital in South West Nigeria. *Ecancermedicalscience.* 2021 Feb  
863 25;15:1192. doi: 10.3332/ecancer.2021.1192. PMID: 33889201; PMCID: PMC8043689.
- 864 78. Tiruneh M, Tesfaw A, Tesfa D. Survival and Predictors of Mortality among Breast Cancer  
865 Patients in Northwest Ethiopia: A Retrospective Cohort Study. *Cancer Manag Res.* 2021 Dec  
866 16;13:9225-9234. doi: 10.2147/CMAR.S339988. PMID: 34938122; PMCID: PMC8687444.
- 867 79. Muddather HF, Elhassan MMA, Faggad A. Survival Outcomes of Breast Cancer in Sudanese  
868 Women: A Hospital-Based Study. *JCO Glob Oncol.* 2021 Feb;7:324-332. doi:  
869 10.1200/GO.20.00538. PMID: 33617296; PMCID: PMC8081542.
- 870 80. Wambua MD, Degu A, Tegegne GT. Treatment outcomes and its associated factors among breast  
871 cancer patients at Kitui Referral Hospital. *SAGE Open Med.* 2022 Jan 8;10:20503121211067857.  
872 doi: 10.1177/20503121211067857. PMID: 35024144; PMCID: PMC8744162.
- 873 81. Wuraola FO, Olasehinde O, Di Bernardo M, Akinkuolie AA, Adisa AO, Aderounmu AA,  
874 Mohammed TO, Omoyiola OZ, et al. Breast cancer in elderly patients: a clinicopathological  
875 review of a Nigerian database. *Ecancermedicalscience.* 2022 Dec 8;16:1484. doi:  
876 10.3332/ecancer.2022.1484. PMID: 36819793; PMCID: PMC9934965.
- 877 82. Matheka M, Mutebi M, Sayed S, Shah J, Shaikh AJ. Metastatic breast cancer in Kenya: survival,  
878 prognosis and management at a tertiary referral centre. *Ecancermedicalscience.* 2023 Jun  
879 27;17:1566. doi: 10.3332/ecancer.2023.1566. PMID: 37396100; PMCID: PMC10310329.
- 880 83. Gnanngnon FHR, Parenté A, Aboubakar M, Kiki-Migan Y, Totah T, Gbessi DG, Tonato-Bagnan  
881 JA, Laleye A, et al. Prognostic factors and overall survival of breast cancer in Benin: a hospital-  
882 based study. *BMC Womens Health.* 2024 May 18;24(1):295. doi: 10.1186/s12905-024-03114-y.  
883 PMID: 38762733; PMCID: PMC11102149.
- 884 84. Soliman M. Squamous cell carcinoma of the breast: A retrospective study. *J Cancer Res Ther.*  
885 2019 Jul-Sep;15(5):1057-1061. doi: 10.4103/jcrt.JCRT\_303\_17. PMID: 31603110.
- 886 85. Olasehinde O, Alatise O, Omisore A, Wuraola F, Odujoko O, Romanoff A, Akinkuolie A,  
887 Arowolo O, et al. Contemporary management of breast cancer in Nigeria: Insights from an  
888 institutional database. *Int J Cancer.* 2021 Jun 15;148(12):2906-2914. doi: 10.1002/ijc.33484.  
889 Epub 2021 Feb 9. PMID: 33506499; PMCID: PMC8394611.
- 890 86. Chokunonga E, Borok MZ, Chirenje ZM, Nyabakau AM, Parkin DM. Cancer survival in Harare,  
891 Zimbabwe, 1993-1997. *IARC Sci Publ.* 2011;(162):249-55. PMID: 21675430.
- 892 87. Bah E, Sam O, Whittle H, Ramanakumar A, Sankaranarayanan R. Cancer survival in the Gambia,  
893 1993-1997. *IARC Sci Publ.* 2011;(162):97-100. PMID: 21675410.
- 894 88. Wabinga H, Parkin DM, Nambooz S, Amero J. Cancer survival in Kampala, Uganda, 1993-  
895 1997. *IARC Sci Publ.* 2011;(162):243-7. PMID: 21675429.



- 896 89. Otu AA, Ekanem IO, Khalil MI, Ekpo MD, Attah EB. Characterization of breast cancer  
897 subgroups in an African population. *Br J Surg.* 1989 Feb;76(2):182-4. doi:  
898 10.1002/bjs.1800760225. PMID: 2702455.
- 899 90. Okobia MN, Osime U. Clinicopathological study of carcinoma of the breast in Benin City. *Afr J*  
900 *Reprod Health.* 2001 Aug;5(2):56-62. PMID: 12471913.
- 901 91. Elhaj AM, Abdalsalam AI, Abuidris AO, Eltayeb AA. Overall survival of females with breast  
902 cancer in the National Cancer Institute, University of Gezira, Sudan. *Sudan Medical Monitor.*  
903 2015;10(1):1-6. doi: 10.4103/1858-5000.157499.
- 904 92. Mensah AC, Yarney J, Nokoe SK, Opoku S, Clegg-Lamptey JN. Survival outcomes of breast  
905 cancer in Ghana: an analysis of clinicopathological features. *Open Access Library Journal.*  
906 2016;3(1):e2145. doi: 10.4236/oalib.1102145.
- 907 93. Joko-Fru WY, Miranda-Filho A, Soerjomataram I, Egue M, Akele-Akpo MT, N'da G, Assefa M,  
908 Buziba N, Korir A, et al. Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis  
909 and human development index: A population-based registry study. *Int J Cancer.* 2020 Mar  
910 1;146(5):1208-1218. doi: 10.1002/ijc.32406. Epub 2019 Jun 14. PMID: 31087650; PMCID:  
911 PMC7079125.
- 912 94. Some OR, Bague AH, Konkobo D, Hien D, Dembele A, Hermann Belemiliga GL, Konsegre V,  
913 Zongo N. Le Cancer du Sein à Bobo-Dioulasso, Burkina Faso: Résultats de la Prise en Charge.  
914 *Oncologie.* 2022;24(2):173-184. doi: 10.32604/oncologie.2022.021250.
- 915 95. Gondos A, Brenner H, Wabinga H, Parkin DM. Cancer survival in Kampala, Uganda. *Br J*  
916 *Cancer.* 2005 May 9;92(9):1808-12. doi: 10.1038/sj.bjc.6602540. PMID: 15827554; PMCID:  
917 PMC2362045.
- 918 96. Traore B, Keita M, Toure A, Camara I, Barry A, Koulibaly M. Impact of surgery associated with  
919 radiotherapy on the prognosis of breast cancer - Guinea Breast Cancer Cohort Study. *Cancer Rep*  
920 *(Hoboken).* 2022 Sep;5(9):e1554. doi: 10.1002/cnr2.1554. Epub 2021 Sep 22. PMID: 34549551;  
921 PMCID: PMC9458488.
- 922 97. Maajani K, Jalali A, Alipour S, Khodadost M, Tohidinik HR, Yazdani K. The Global and  
923 Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis.  
924 *Clin Breast Cancer.* 2019 Jun;19(3):165-177. doi: 10.1016/j.clbc.2019.01.006. Epub 2019 Jan 29.  
925 PMID: 30952546.
- 926 98. Quang DT, Luong Thi T, Nguyen Di K, Vu Thi Quynh C, Nguyen Thi Hoa H, Phan Ngoc Q.  
927 Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review  
928 and meta-analysis spanning four decades. *Curr Probl Cancer.* 2024 Feb;48:101062. doi:  
929 10.1016/j.currprobcancer.2024.101062. Epub 2024 Feb 2. PMID: 38309146.
- 930 99. Maajani K, Khodadost M, Fattahi A, Pirouzi A. Survival rates of patients with breast cancer in  
931 countries in the Eastern Mediterranean Region: a systematic review and meta-analysis. *East*  
932 *Mediterr Health J.* 2020 Feb 24;26(2):219-232. doi: 10.26719/2020.26.2.219. PMID: 32141601.
- 933 100. Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, López Gómez M, Casado E.  
934 Male breast cancer. *Cancer Treat Rev.* 2010 Oct;36(6):451-7. doi: 10.1016/j.ctrv.2010.02.002.  
935 Epub 2010 Mar 2. PMID: 20193984.
- 936 101. Scomersi S, Giudici F, Cacciatore G, Losurdo P, Fracon S, Cortinovis S, Ceccherini R, Zanconati  
937 F, Tonutti M, Bortul M. Comparison between male and female breast cancer survival using  
938 propensity score matching analysis. *Sci Rep.* 2021 Jun 2;11(1):11639. doi: 10.1038/s41598-021-  
939 91131-4. PMID: 34079019; PMCID: PMC8172634.
- 940 102. Gwark S, Kim J, Chung IY, Kim HJ, Ko BS, Lee JW, Son BH, Ahn SH, Lee SB. Survival pattern  
941 in male breast cancer: distinct from female breast cancer. *Front Oncol.* 2024 Jun 28;14:1392592.  
942 doi: 10.3389/fonc.2024.1392592. PMID: 39007102; PMCID: PMC11239393.

- 943 103. Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Larønningen S, Mellekjær L,  
944 Czene K, Hartman M. Incidence and outcome of male breast cancer: an international population-  
945 based study. *J Clin Oncol*. 2011 Nov 20;29(33):4381-6. doi: 10.1200/JCO.2011.36.8902. Epub  
946 2011 Oct 3. PMID: 21969512.
- 947 104. Varzaru VB, Anastasiu-Popov DM, Eftenoiu AE, Popescu R, Vlad DC, Vlad CS, Moatar AE,  
948 Puscasiu D, Cobec IM. Observational Study of Men and Women with Breast Cancer in Terms of  
949 Overall Survival. *Cancers (Basel)*. 2024 Sep 1;16(17):3049. doi: 10.3390/cancers16173049.  
950 PMID: 39272907; PMCID: PMC11394319.
- 951 105. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, et  
952 al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA*. 2006  
953 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492. PMID: 16757721.
- 954 106. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, et al.  
955 NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. *J Natl Compr Canc Netw*. 2021  
956 May 1;19(5):484-493. doi: 10.6004/jnccn.2021.0023. PMID: 34794122.
- 957 107. Morris GJ, Mitchell EP. Higher incidence of aggressive breast cancers in African-American  
958 women: a review. *J Natl Med Assoc*. 2008 Jun;100(6):698-702. doi: 10.1016/s0027-  
959 9684(15)31344-4. PMID: 18595572.
- 960 108. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T. Metastatic and triple-negative breast  
961 cancer: challenges and treatment options. *Drug Deliv Transl Res*. 2018 Oct;8(5):1483-1507. doi:  
962 10.1007/s13346-018-0551-3. PMID: 29978332; PMCID: PMC6133085.
- 963 109. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van  
964 Laarhoven HW, et al. Triple-negative breast cancer: present challenges and new perspectives. *Mol*  
965 *Oncol*. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. PMID:  
966 20537966; PMCID: PMC5527939.
- 967 110. Martini R, Chen Y, Jenkins BD, Elhussin IA, Cheng E, Hoda SA, Ginter PS, Hanover J, et al.  
968 Investigation of triple-negative breast cancer risk alleles in an International African-enriched  
969 cohort. *Sci Rep*. 2021 Apr 29;11(1):9247. doi: 10.1038/s41598-021-88613-w. PMID: 33927264;  
970 PMCID: PMC8085076.
- 971 111. Koon Sun Pat M, Manraj M, Manraj S. Breast cancer survival analysis in the Republic of  
972 Mauritius by age, stage at diagnosis and molecular subtype: A retrospective cohort study. *Int J*  
973 *Cancer*. 2025 Jan 15;156(2):331-338. doi: 10.1002/ijc.35172. Epub 2024 Sep 7. PMID:  
974 39243396.
- 975 112. Sanyang O, Lopez-Verdugo F, Mali M, Moustafa M, Nellerme J, Sorensen J, Bittaye M, Njie R,  
976 et al. Geospatial analysis and impact of targeted development of breast cancer care in The  
977 Gambia: a cross-sectional study. *BMC Health Serv Res*. 2021 Sep 9;21(1):943. doi:  
978 10.1186/s12913-021-06963-7. PMID: 34503503; PMCID: PMC8428029.
- 979 113. World Health Organization. Atlas of African Health Statistics 2022: Health situation analysis of  
980 the WHO African Region — Country profiles. Brazzaville: WHO Regional Office for Africa.  
981 2022 [online]. Available from [https://www.afro.who.int/publications/atlas-african-health-](https://www.afro.who.int/publications/atlas-african-health-statistics-2022-health-situation-analysis-who-african-region-0)  
982 [statistics-2022-health-situation-analysis-who-african-region-0](https://www.afro.who.int/publications/atlas-african-health-statistics-2022-health-situation-analysis-who-african-region-0) (accessed 30th November 2024).
- 983 114. Lombe DC, Mwamba M, Msadabwe S, Bond V, Simwinga M, Ssemata AS, Muhumuza R, Seeley  
984 J, Mwaka AD, et al. Delays in seeking, reaching and access to quality cancer care in sub-Saharan  
985 Africa: a systematic review. *BMJ Open*. 2023 Apr 13;13(4):e067715. doi: 10.1136/bmjopen-  
986 2022-067715. PMID: 37055211; PMCID: PMC10106057.
- 987 115. Round JI. Globalization, Growth, Inequality and Poverty in Africa: A Macroeconomic  
988 Perspective. Research Paper 2007/055 Helsinki: UNU-WIDER. 2007 [online]. Available from

- 989 <https://www.wider.unu.edu/publication/globalization-growth-inequality-and-poverty-africa>  
990 (accessed 30th November 2024).
- 991 116. Ichoku HE, Mooney G, Ataguba JE. Africanizing the social determinants of health: embedded  
992 structural inequalities and current health outcomes in sub-Saharan Africa. *Int J Health Serv.*  
993 2013;43(4):745-59. doi: 10.2190/HS.43.4.i. PMID: 24397237.
- 994 117. James PB, Asiimwe JB, Wardle J, Mwaka AD, Kasilo OMJ. African culture, traditional medicine,  
995 and cancer care. *Lancet Oncol.* 2022 Jun;23(6):705-706. doi: 10.1016/S1470-2045(22)00157-7.  
996 Epub 2022 May 9. PMID: 35550271.
- 997 118. Tetteh DA, Faulkner SL. Sociocultural factors and breast cancer in sub-Saharan Africa:  
998 implications for diagnosis and management. *Womens Health (Lond).* 2016 Jan;12(1):147-56. doi:  
999 10.2217/whe.15.76. Epub 2016 Jan 12. PMID: 26757491; PMCID: PMC5779571.
- 1000 119. Mansour R, Abdel-Razeq H, Al-Hussaini M, Shamieh O, Al-Ibraheem A, Al-Omari A, Mansour  
1001 AH. Systemic Barriers to Optimal Cancer Care in Resource-Limited Countries: Jordanian  
1002 Healthcare as an Example. *Cancers (Basel).* 2024 Mar 11;16(6):1117. doi:  
1003 10.3390/cancers16061117. PMID: 38539452; PMCID: PMC10968872.
- 1004 120. Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage at diagnosis of breast  
1005 cancer in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health.* 2016  
1006 Dec;4(12):e923-e935. doi: 10.1016/S2214-109X(16)30259-5. PMID: 27855871; PMCID:  
1007 PMC5708541.